AcelRx Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Talphera

15/11/2021 14:31

* AcelRx Pharmaceuticals Inc  ACRX.OQ  reported a quarterly
adjusted loss of 7 cents​​ per share for the quarter ended in
September. The mean expectation of two analysts for the quarter
was for a loss of 7 cents per share.
* Revenue rose 36.1% to $1.86 million from a year ago;  analysts
expected $1.90 million. 
* AcelRx Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 7 cents​.
* The mean earnings estimate of analysts had fallen by
about 16.7% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* AcelRx Pharmaceuticals Inc shares had fallen by 22.1% this
quarter and lost 35.9% so far this year.
* The company reported a quarterly loss of $8.38 million.
* Wall Street's median 12-month price target for AcelRx
Pharmaceuticals Inc is $5.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 15 at 02:31 p.m.
 ​All figures in US dollars unless otherwise stated